Objective To compare the efficacy and safety of linezolid versus vancomycin in treatment of pneumonia caused by methicillin-resistant Staphylococcus aureua ( MRSA) in ICU. Methods Between May 2008 and November 2010,72 patients with MRSA pneumonia were admitted to Wenzhou Traditional Chinese Medicine Hospital. The patients received 600 mg linezolid or 1 g vancomycin every 12 h daily. The therapeutic effect,bacterial clearance and adverse events were compared between the two treatments. Results The rates of full recovery and overall response were 25. 7% and 65.1% for vancomycin versus 18.9% and 51.4% for linezolid in the treatment of MRSA infection. The bacterium clearance rates were 71. 4% and 48. 6% ;and the incidence of side effects were 8. 5% and 5.4% .respectively. There were no significant differences between the two groups in terms of full recovery, bacterial clearance and overall incidence of adverse effects (P > 0. 05). Conclusion For treatment of MRSA infections,Linezolid is similar to vancomycin in microbial susceptibility,overall efficacy,good safety and patient tolerance. Linezolid may be more effective than vancomycin in microbiological eradication from sputum.%目的 比较利奈唑胺与万古霉素对ICU患者耐甲氧西林金黄色葡萄球菌(MRSA)肺部感染的疗效及安全性.方法 对2008年5月至2010年11月温州市中医院收治的72例肺部MRSA感染的患者,分别给予利奈唑胺(0.6g/次,每日2次)和万古霉素(1.0g/次,每日2次)治疗,观察并比较两种方法的临床疗效、细菌学疗效及不良反应.结果 万古霉素与利奈唑胺治疗MRSA的治愈率分别为25.7%和18.9%,临床总有效率分别为65.7%和51.4%,细菌清除率分别为71.4%和48.6%,不良反应总发生率为8.5%和5.4%,两组间MRSA治愈率、总有效率和不良反应总发生率比较差异无统计学意义(P＞0.05),细菌清除率比较差异有统计学意义(P＜0.05).结论 对于ICU患者肺部MRSA感染,利奈唑胺与万古霉素敏感率均很高,总体疗效相似,且安全性及耐受性较好,利奈唑胺痰菌清除率略高于后者.
展开▼
